Results 171 to 180 of about 4,816,902 (277)

Correction: Lifetime prevalence of novel psychoactive substances use among adults in the USA: Sociodemographic, mental health and illicit drug use correlates. Evidence from a population-based survey 2007-2014. [PDF]

PLoS One, 2021
Neicun J, Yang JC, Shih H, Nadella P, van Kessel R, Negri A, Czabanowska K, Brayne C, Roman-Urrestarazu A.   +8 more
europepmc   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Computational Approach to Select Lead-Like Compounds From an Opioid Class of Novel Psychoactive Substances. [PDF]

Chem Biodivers
Arsić B, Micić R, Kostić E, Micić A, Lukić V.   +4 more
europepmc   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Legislating novel psychoactive substances: lessons from 15 years of UK mortality data (2007-2022). [PDF]

Front Pharmacol
Rock KL, Treble R, Copeland CS.
europepmc   +1 more source

The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial

Addiction, EarlyView.
Abstract Background and aims Ketamine assisted psychotherapy is a promising new treatment for alcohol use disorder (AUD). The psychoactive effects of repeated intravenous (IV) ketamine infusions in people with AUD and their mechanistic role in treating AUD are largely unknown.
Cassie Bloy, Ananya Sarma, Bethan Marsh, Lorna Hardy, Meryem Grabski, Merve Mollaahmetoglu, Joshua Shotton, Shamhethan Bhaskaran, Anne Lingford‐Hughes, H. Val Curran, Celia Morgan, Will Lawn   +11 more
wiley   +1 more source

Global Patterns of Fatalities With Toxicological Detection of Novel Psychoactive Substances: A Systematic Review and Meta-analysis. [PDF]

Cureus
Tyagi S, Singh JP, Manzoor A, Basra S, Sharma Y, Sharma P, Shubham, Kaur A, Kaur S.   +8 more
europepmc   +1 more source

How deaths can help clinicians and policy-makers understand the risks of novel psychoactive substances. [PDF]

Br J Clin Pharmacol, 2020
Corkery JM, Schifano F, Martinotti G.
europepmc   +1 more source

Associations of cannabis use, tobacco use and co‐use with brain volume: A systematic review and meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer, Tom P. Freeman, Martine Skumlien, Esther Walton, Thomas Lancaster, Jorien L. Treur, Valentina Lorenzetti, Anna K. M. Blackwell, Chloe Burke, Richie J. Carr, Constantinos Constantinides, Maisie Cox, Sarah Dance, Shadi Daryan, Sorcha Hamilton, Tom Jenkins, Gemma M. J. Taylor   +16 more
wiley   +1 more source

Emergency department-based testing for xylazine and other novel psychoactive substances in Central Alabama: a feasibility study. [PDF]

Harm Reduct J
Bradford W, Dye D, Jensen R, Bratches R, Marshall S, Eaton E, Figgatt M, Taylor W, Walter LA, Goodman-Meza D, Kertesz S, Scott KS.   +11 more
europepmc   +1 more source